Neurol Clin. Author manuscript; available in PMC 2012 Feb 1.
Published in final edited form as:
Scott D. Lane, Ph.D., Professor, Kimberly L. Kjome, M.D., Assistant Professor, and F. Gerard Moeller, M.D., Professor
Author information Copyright and License information PMC Disclaimer
The publisher's final edited version of this article is available at Neurol Clin
Synopsis
Aggression is a serious medical problem that can place both the patient and the health care provider at risk. Aggression can result from medical, neurologic and or psychiatric disorders. A comprehensive patient evaluation is needed. Treatment options include pharmacotherapy as well as non-pharmacologic interventions, both need to be individualized to the patient.
Keywords: Aggression, pharmacotherapy, diagnosis, neurobiology
Introduction
Before embarking on any discussion of the etiology and treatment of aggression, it is important to clearly define what is meant by aggression. Aggressive behavior is prevalent in most species, and aggressive behavior patterns may serve an adaptive function. In humans however, extreme and persistent forms of aggression are often indicative of psychopathology 1, especially when they persist across the lifetime 2, 3.
While several definitions have been proposed, here we will operationally define human aggression as (a) a social behavior that involves the interaction at least two people; (b) is intended to harm another person; who (c) finds this harm aversive and would act to avoid it 4, 5. Note that this definition includes the requirement of a social context (i.e., verbal and non-verbal interaction). Thus, aggression directed toward self (i.e., self-injury, suicide) rests outside the scope of this chapter. Importantly, provocation and retaliation are known to be critical determinants of aggression, and these factors necessarily require a social context 6.
2. Brain regions associated with pathologic aggression
In general, data from both human and non-human studies find that subcortical brain regions, particularly the limbic system and specifically the amygdala, are associated with the processing of emotionally salient events, including aggression 7. The limbic system consists of several components that interact with each other and project to areas of autonomic and somatomotor emotional control 8. The amygdala has repeatedly been shown to mediate fear, defensive reactions, emotional learning, and motivation 7. The amygdala and hypothalamus interact in the emotions of anger and fear 9. Patients with damage to the amygdala show impairment in the recognition of fearful facial expressions 10, and the amygdala is active in a number of human social conditioning and fear paradigms 11.
In addition to subcortical regions, several cortical brain regions have been associated with emotions. The dorso-lateral pre-frontal cortex (DLPFC) and the orbito-frontal cortex (OFC) receive limbic inputs from amygdala and other medial temporal areas as well as sensory inputs, and thus may integrate sensory information with affective signals 12. Damage to limbic and pre-frontal cortex (PFC) regions negatively affect cognition, memory, and emotional processes 13. Several theories propose that (a) it is the interconnected network between the limbic (amygdala), OFC, and DLPFC regions that primarily subserve the processing of emotional and goal driven behavior (e.g., “hedonic” function), and (b) damage or dysfunction in any of these areas or this network results in problems with the regulation of emotion and subsequent difficulties with inhibitory and aggressive behavior 14.
There is considerable evidence that the limbic-dorsolateral prefrontal-and orbital frontal network facilitates the activation and inhibition of aggressive behavior. Patients with brain lesions in OFC have higher aggression/violence scores compared to normal controls and patients with lesions in other brain regions 15. Following frontal lobe damage, particularly injury to the ventro-medial prefrontal cortex, subjects who exhibited sociopathic behavior showed decreased autonomic skin conductance responses to emotional visual stimuli 13. Alzheimer’s patients presenting problems with behavioral disinhibition showed decrements in OFC, DLPFC, and anterior cingulate metabolic activity that were not present in Alzheimer dementia patients without such problems 16. In patients with organic mental syndromes and violent behavior, lesions in the amygdala-hippocampal region were found in brain imaging scans that were not present in non-violent organic patients 17. These studies concluded that widespread damage to the amygdala (as opposed to pinpoint surgical lesions) produces behavioral disinhibition and violent behavior.
The connection between neuropsychiatric abnormalities and violent criminal behavior noted that “orbitofrontal injury is specifically associated with aggression” and “focal frontal lobe dysfunction is associated with aggressive dyscontrol and increased risk of violence” 18. Similarly, the neurobiology of personality disorders concluded that impulsive aggression is characterized by abnormal functioning in the amygdala, OFC, DLPFC, and anterior cingulate cortex (ACC) 19. Psychiatric patients with a history of repetitive purposeless violent behavior showed lower resting temporal and prefrontal metabolic activity compared to normal controls 20. There was a significant inverse correlation between life history of aggressive impulse difficulties and OFC regional metabolic activity 21. Subjects who committed unplanned impulsive murders were found to have lower PFC and higher subcortical (e.g., amygdala, hippocampus) metabolic activity compared to controls 22. Patients with DSM-IV personality disorders and clinically significant impulsive aggression showed an absence of activation in OFC and ACC in response to the serotonin agonist drug m-CPP 23. Individuals with a criminal history of domestic violence who also met alcohol dependence criteria had lower metabolic activity in hypothalamus, thalamus, and OFC than both non-violent alcoholics and healthy controls 24. Neuroimaging studies that experimentally induced anger in humans demonstrated increased activation in the DLPFC and OFC 25. In non-human primates, OFC and DLPFC lesions reliably produce increased aggressive behavior 26.
The brain neuronal circuitry underlying aggressive behavior appears quite extensive and complex. Studies in humans suggest that increased aggressive behavior may be associated with decreased functioning in orbital and dorsolateral prefrontal cortical areas, and increased functioning in medial temporal (especially amygdala) brain regions. Importantly, the relative balance of activity between dorsolateral prefrontal, orbital frontal, and limbic brain regions may be important in predisposing to violence and abnormal processing of emotional stimuli 18.
3. Seizures and aggression
There have been medical legal cases in which epilepsy has been used as a defense against charges of violence. However, recent studies provide evidence that that acts of aggression during seizures are simple and unsustained; they are not planned or carried out in an organized fashion, nor are they purposeful or directed. When aggression occurs in the setting of a seizure the onset is usually sudden, duration is short, and the act is generally in response to being held down or as part of a defensive motion. Seizure related aggression is usually part of an automatism which is characteristically unsustained, short lived or fragmentary. 27.
To better understand the relation between aggression and epilepsy, an international task force from 16 epilepsy programs, selected 19 pts who were thought to have aggressive behavior during their seizure. This sample of patients was selected from a group of 5400 patients with epilepsy. The events were recorded by video-monitoring EEG and analyzed. After reviewing the clinical characteristics and their correlation with electroencephalographic (EEG) discharges, the task force made recommendations to guide the determination of causation of aggression in patients with epilepsy 28;
1) the diagnosis of epilepsy should be established by a neurologist with special training in epilepsy, 2) the presence of epileptic automatisms should be documented by history, closed circuit television monitoring and EEG bio telemetry, 3) presence of aggression during epileptic automatisms should be verified by videotaped recorded seizures and correlated with EEG ictal epileptiform discharges. 4) the aggressive or violent episode should be characteristic of the patient’s habitual seizures at which point 5) a clinical judgment should be made by the neurologist who will then attest if in his or her opinion the act and or alleged crime was part of the seizures. 28.
A complete history including clinical characteristics, medical, psychiatric comorbidites, social history other concomitant factors and circ*mstances are essential prior to making a diagnosis and before designing a necessary treatment.
4. Dementia and aggression
Patients with dementia can present with aggression and or agitation. Symptoms can be due to a superimposed delirium, and or to the nature and severity of the underlying degenerative or structural etiology. Identifying and treating the underlying etiology is key to maximizing outcome. As reviewed in Ballard 29, agitation and aggression are frequent symptoms in patients with dementia, which are distressing to family members and can lead to significant morbidity. In a retrospective review of patients who were diagnosed with Alzheimer’s disease conducted by Jost et al. symptoms were defined in 3 groups to include agitation, mood symptoms and psychotic symptoms. The authors found that agitation occurred in the first year after the diagnosis, psychotic symptoms at the time of the diagnosis, and mood symptoms preceded the diagnosis on the average by two years. A comprehensive approach to these patients should include basic testing of cognitive functions as it might lead us an early accurate diagnosis with all the necessary implications. 30
5. Aggression and Psychiatric Diagnosis
Intermittent Explosive Disorder
DSM-IV-TR Diagnostic Criteria for Intermittent Explosive Disorder: A. Several discrete episodes of failure to resist aggressive impulses that result in serious assaultive acts or destruction of property. B. The degree of aggressiveness expressed during the episodes is grossly out of proportion to any precipitating psychosocial stressors. C. The aggressive episodes are not better accounted for by another mental disorder and are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition (e.g., head trauma, Alzheimer’s disease). As can be seen from the Diagnostic and Statistical Manual version IV Text Revision (DSM-IV-TR) criteria for Intermittent explosive disorder (IED) listed above, aggression is a key feature of the diagnosis 31. An additional key feature of the diagnosis of IED is the fact that it is a diagnosis of exclusion; if the aggression is thought to be better accounted for by another psychiatric or non-psychiatric medical condition, the diagnosis of IED cannot be made. However, the determination of whether the aggression is better accounted for by another condition is left to the clinician, with little guidance on how this determination is to be made. In some cases the determination is relatively simple. In a situation where a patient who has no history of aggression prior to a head injury suddenly develops aggression after the injury the diagnosis of aggression related to the brain injury would be made to the exclusion of IED. In many cases however, the diagnosis is less clear. Many patients with aggressive behavior have minor head trauma and substance abuse and the causal relationship between these factors and the aggression can be difficult to ascertain. Obtaining information from friends and family of the patient regarding the association between aggression and other potential factors such as substance abuse or head trauma is critical in the determination of the causal relationship. As with the general evaluation of aggression regardless of the etiology, a thorough history and physical examination and neurologic examination are also important. Factors such as rapid onset of symptoms, association with neurological findings on physical examination, or frontal release signs (described in detail in the diagnostic evaluation section below) can be a reason for additional tests, such as neuropsychological testing and MR brain imaging. From a treatment perspective, unless the aggression is clearly better accounted for by another psychiatric diagnosis or non-psychiatric medical condition, the critical question is whether the aggression is primarily impulsive or planned. Impulsive aggression has been shown to respond to treatment with pharmacotherapy, while planned or premeditated aggression has not.
Aggression and psychosis
The relationship between aggression and psychotic disorders in particular schizophrenia is controversial. 32. One potential reason for the conflicting results on the association between psychosis and aggression is the fact that past history of aggressive behavior related to antisocial personality disorder and substance abuse are independently associated with aggression, and thus need to be taken into account in the study of psychosis and violence. Taking these factors into account, there is some evidence that psychosis accompanied by depression or distress is associated for a increased risk of violence 32.
Aggression and substance abuse
Alcohol
The epidemiological evidence linking alcohol to aggressive behavior is overwhelming. Alcohol intoxication, abuse and dependence are highly associated with violent criminal activity 33, 34. The non-health related costs of alcohol abuse to society, e.g., those resulting from criminal behavior, are estimated at $13 billion annually 35. A substantial proportion of these crimes are of a violent nature; alcohol may be involved in 40 to 50% of all violent crimes, including homicide and assault 36. This pattern is present in adolescents and young adults 37. There is a positive correlation between the quantity of ethanol consumed and the frequency of a wide variety of acts of violence including sexual assault, child abuse, and homicide 38. Individuals who engage in aggressive behavior report a greater amount of ethanol consumption than those without such a history 39. Additionally, alcohol consumption is greater in individuals who are more likely to commit violence, such as individuals with (Antisocial Personality Disorders) ASPD 1.
There is an extensive history of laboratory investigation regarding alcohol effects on aggression 40, 41. Reviews of laboratory-based studies have consistently concluded that alcohol increases aggressive responding 38, 41. More than any other drug, alcohol is known to increase the probability of aggression under laboratory conditions 41.
Other Abused Drugs
Historically, a number of benzodiazepines have been used effectively to manage aggression in psychiatric patient populations 42. However, previous reports have noted an association between benzodiazepine use and aggressive/violent behavior 43. Past reviews have documented increased risk of criminal behavior following extended use 44 and loss of self-control and violence in patient populations prescribed benzodiazepines 45. From the extant data, it is unknown if these increases were observed primarily in individuals with a history of violent behavior or underlying personality disorder. Recreational use of flunitrazepam (Rohypnol) increased the odds of involvement in physical assault, sexual assault, and motor vehicle accidents 46. A survey of Mexico City drug users an association between flunitrazepam abuse and street fights, robbery, and rape 47. In forensic studies psychiatric patients and juvenile offenders who abused flunitrazepam were more commonly involved in offenses involving robbery, weapons, and drugs 48, acts of impulsive violence, and serious violent criminal offenses 49. Thus, like alcohol, abuse of certain benzodiazepines may be related to aggression. This may to due to shared pharmacological mechanisms of action at GABA receptors, and concomitant loss of inhibitory control. However, because benzodiazepines have also been shown to be clinically effective in mitigating agitation and aggressive behavior, it appears likely that there is a subset of individuals for whom heavy use or abuse of benzodiazepines may facilitate aggressive behavior. History of criminal violence and/or personality disorders may be contributing factors.
One previous literature review concluded that there was little evidence suggesting that marijuana use was directly associated with aggressive behavior 50. However, more recent data suggest that marijuana use may be related to increased likelihood of violence, with particularly relevance to use during adolescence. Studies show increased likelihood of weapons offenses and attempted homicide in inner city low-SES youth 51; a link between marijuana use during early adolescence and violence experiences in later adolescence in Columbian youth 52; heavy use and abuse of marijuana was predictive of violent crimes (vs. property crimes) in delinquent adolescents 53; and violent behavior during adolescence was associated marijuana use and dependence in early adulthood 54. The complexity of this relationship cannot be underemphasized. Developmental factors and comorbid conduct/behavior disorders highlight the difficulty of understanding direction and causality in the relationship between marijuana use and aggression. Further complexity is added by studies suggesting that aggressive behavior may increase during periods of marijuana withdrawal 55.
Several studies suggest a relationship between aggressive behavior and the use of CNS stimulants. Day to day substance use in males was related to violence toward female partners, with cocaine and/or alcohol use associated with increases in physical aggression 56. Denison et al., 57 reported that violent behavior increased during periods of cocaine and/or cocaine-alcohol use, and that the severity of violence was altered once cocaine use escalated into cocaine dependence. Dysregulation of the limbic system following chronic has been suggested as a mechanism by which cocaine use may lead to heightened aggression 58, 59. In support, Moeller et al., 60 found that, compared to controls, cocaine dependent subjects were more aggressive than control subjects on both psychometric and laboratory measures of aggression; and further showed a significant correlation between measures of aggression and growth hormone response to a buspirone challenge, which was not observed in controls. However, a subsequent study Moeller et al., 61 suggested that the relationship between cocaine-use variables (e.g., craving, withdrawal) and aggression is mediated primarily by the presence of antisocial personality disorder. In addition to cocaine, aggressive behavior patterns may be associated with the abuse of other CNS stimulants including methamphetamine 62 and 3,4-methylenedioxy-methamphetamine (MDMA or “Ecstacy”) 63.
Epidemiological data indicate that, generally, the presence of a psychiatric disorder increases risk for violent behavior, but this risk is greatly increased by the presence of substance abuse symptoms 64. Most prominent is the finding that comorbid substance use disorders and Axis-II personality disorders (particularly conduct, antisocial personality, and borderline personality disorders) increase the risk for violent behavior above either disorder alone; by one account on the order 15–20:1 compared to community-matched base rates 64. Adolescent drug users were more prone to fighting and assault than non-drug users, and were more likely to be victims of violent behavior 65. The collective implication of such data is that, at least in natural settings, rather than a direct pharmacological effect of abused drugs on aggressive behavior, there are important interactions with concomitant factors such as history of aggressive behavior and presence of psychiatric disorders that must be understood.
Diagnostic evaluation of aggression
History and Presentation
Aggression is a behavioral finding of many etiologies, necessitating a detailed history and physical exam in establishing the cause and potential treatments. A comprehensive approach to include premorbid function, prior psychiatric and medical comorbidities, history of alcohol and or substance abuse, concomitant medications, presence of absence of social support, and coping mechanisms is imperative as identifying and treating the underlying etiology is key to maximizing outcome.
Specific questions in the history about aggression may help characterize illness and inform clinicians about the potential for future aggressive acts. Legal history including reason for, number and length of incarcerations, history of abuse toward spouse, child or other person or animals should be obtained as well as ownership and carrying pattern of firearms. Developmental components relating to patterns of abuse and childhood environment as well as developmental delays, childhood legal history, diagnosis with conduct disorder or oppositional defiant disorder may also help to further characterize presentation of aggression.
Physical Examination
In general, a basic evaluation for aggressive behavior should include a complete medical, neurological and psychiatric evaluation. Laboratory tests should include a CBC, metabolic panel, thyroid functions, urine drug screen, and urinalysis. In addition, although of lower yield, B12, and folate levels may be helpful. Brain imaging and EEG may be indicated based on the history and physical exam findings as described below.
Physical findings in individuals with aggressive behavior of psychiatric origin, while generally nonspecific may be helpful at understanding underlying causes of aggression. Likewise, as mentioned previously, a diagnosis of intermittent explosive disorder is made by exclusion of non-psychiatric medical causes of aggression. Hence, this diagnosis can only be made after a thorough medical evaluation.
Abnormal vital signs and or acute change in mental status may suggest delirium and should be investigated. In institutionalized patients with dementia, urinalysis and chest-x rays may be particularly helpful in determining the cause of delirium.
Sudden change in behavior or focal neurologic findings suggest focal brain pathology that should be evaluated by MRI or CT scans. Gradual decline in cognitive functioning concomitant with aggression suggests dementia, which would necessitate a thorough workup for causes of dementia, including brain imaging, neuropsychological testing, and EEG.
Additional findings on physical exam may include signs of past physical altercations, including healed signs of fracture, contusion, laceration, gunshot wound and other signs of violence. Frontal release signs may direct the history and evaluations towards a diagnosis of dementia, skull injuries may suggest a traumatic etiology.
Treatment of aggression
Pharmacotherapy for aggression can be separated into acute and chronic phases. The goal for the treatment of acute aggressive behavior, which is generally initiated in the emergency Department or on an inpatient unit, is elimination of the aggressive behavior for the safety of the patient and staff. In the pharmacotherapy of acute aggression, sedation is accepted and even sought after, while it is considered an unacceptable side effect in the treatment of chronic aggression. With these factors in mind, medications are used for the treatment of acute aggression tend to not have specific effects on aggression but to have substantial sedative effects. A common practice is the use of injectable benzodiazepines and antipsychotic medication, alone or in combination. In a recent Cochrane meta-analysis of studies on the use of benzodiazepines for the treatment of acute aggression, Gillies et al., 66 concluded that the benzodiazepine lorazepam reduced excitement after 24 hours compared to placebo and produced similar sedation to antipsychotic medication. When comparing benzodiazepines plus antipsychotic medication to antipsychotic medication alone, there was no difference in the need for additional medication to achieve sedation between the two treatments but there was a higher rate of extrapyramidal symptoms in the group that received antipsychotic medication alone 66. The finding that patients treated with antipsychotic medication alone had higher rates of extrapyramidal side effects is consistent with the study of Huf et al., who showed that in a group of 316 patients that received intramuscular medication for sedation for aggression subjects who received haloperidol alone had more extrapyramidal symptoms than subjects who received haloperidol plus promethazine 67.
Antipsychotic medications vary in their extrapyramidal side effects based on potency of dopamine receptor antagonism and affinity for other receptors, such as the muscarinic cholinergic receptor, with lower potency antipsychotic medications generally having less extrapyramidal side effects than higher potency antipsychotic medications. There is a growing body of evidence that newer generation antipsychotic medications other than clozapine do not have a specific reduction in extra pyramidal side effects side effects above and beyond the potency and inherent anticholinergic effects 68. However, few controlled trials have compared older generation and newer generation antipsychotic medications for acute aggression.
Pharmacotherapy of Chronic Aggression
As mentioned above, the goal of pharmacotherapy of chronic aggressive behavior is elimination or reduction of aggression without producing general sedation or other intolerable side effects. Although there are a large number of case reports and open label trials of various medications for aggression 69, there are relatively few double blind placebo controlled trials of medication for chronic aggressive behavior. Since there is a substantial placebo effect in the treatment of aggression (similar to virtually every other psychiatric and non-psychiatric medical disorder), it is difficult to assess the efficacy of pharmacotherapy from open label trials and case reports should be evaluated with some skepticism. Listed below are the most commonly used classes of medications for chronic treatment of aggression along with the evidence supporting their use for this indication and potential drawbacks.
Antipsychotic Medication
As described above, antipsychotic medication is used routinely alone or in combination with benzodiazepines or promethazine for the treatment of acute aggression. However, for the treatment of chronic aggressive behavior, where sedation is not an acceptable side effect, there is little evidence to support the use of first generation antipsychotic medication. However, there is some data to support a specific anti-aggressive effect for at least some of the second generation antipsychotic medications.
In children with mental retardation, and autism, and adults with dementia there is data to support a specific anti-aggressive effect which appears to be separate from the sedative effect of risperidone at least at lower doses 29. In a meta-analysis by Ballard and Howard (2006), the conclusions were that risperidone at 1 and 2 mg daily produced a significant improvement in aggression in patients with dementia 70. Further, in patients with schizophrenia, there is evidence that risperidone may reduce aggression to a greater degree than first generation antipsychotic medication 71. The main drawbacks with risperidone are related to side effects of extrapyramidal symptoms, orthostasis, and sedation. As mentioned above, there is a growing body of evidence that newer generation antipsychotic medications do not have lower extrapiramidal side effects than older generation antipsychotic medications 68. In addition, the FDA has added a “black box” warning to risperidone and other antipsychotic medications regarding the increased mortality in elderly dementia patients treated with antipsychotic medication, largely related to cardiovascular or infectious causes 29. Other second generation antipsychotic medications have also been studied for chronic aggression in patients with dementia. In the meta-analysis by Ballard and Howard (2006), in addition to risperidone, olanzapine produced a significant improvement in aggression in patients with dementia at a dose of 5–10 mg per day 70. Less data is available for other second generation antipsychotic medications. One study of quetiapine found a significant worsening of agitation, possibly related to quetiapine’s effects on muscarinic receptors or BDNF72 but one study of aripiprazole did indicate improvement in agitation 73. Similar to findings in dementia patients, there is some evidence from small scale and open label studies that other second generation antipsychotic medications reduce aggression in patients with conduct disorder, but these conclusions need to be replicated in larger controlled studies 74.
One second generation antipsychotic that dose have has some additional evidence that it reduces aggression independent of sedative effects is clozapine 75. The majority of the evidence supporting a specific anti-aggressive effect of clozapine comes from studies of patients with psychosis 76. In addition to the drawbacks of other second generation antipsychotic medications, clozapine also has a risk of a potentially lethal reduction in white blood cell count which limits its use to patients who are refractory to other medications.
Lithium
One of the earliest placebo controlled trials of a medication for chronic aggressive behavior was carried out by Sheard et al., 77, in which 66 male prisoners (age 16 to 24), without a prior history of prior treatment for a psychiatric disorder were treated with lithium or placebo in a double blind fashion for up to three months. Results of the study showed that the subjects treated with lithium had a significant reduction in aggressive behavior compared to the placebo treated subjects.
Since the study by Sheard et al., a number of other studies have examined lithium as a treatment for chronic aggression showing similar results in a variety of patient groups including patients with mental retardation and children with conduct disorder 78, 79. As with anticonvulsants, (described in detail below) there is some evidence that lithium is most effective in patients with affective or impulsive aggression, as opposed to premeditated aggression 80. The main drawbacks with lithium as a treatment for chronic aggression are the side effects and need for blood level monitoring. Lithium has a narrow therapeutic window, with a potential for substantial toxicity if blood levels exceed recommended levels of 0.6 to 1.2 mEq/l. Even if blood levels are maintained in this range, lithium has side effects that include tremor, sedation, nausea, and polyuria; there is some evidence that patients with head trauma may be at greater risk for neurotoxicity, especially if these patients are also taking antipsychotic medication 81.
Anticonvulsants
Anticonvulsant are probably the most widely studied class of medications for treatment of chronic aggression. One of the first double blind placebo controlled trials of anticonvulsants for aggression was carried out by Barratt and colleagues, who compared phenytoin to placebo in inmates with violent behavior 82. In that study subjects were treated with 300 mg of phenytoin daily in divided doses. Results of the study were that inmates who had impulsive aggression showed a significant reduction in aggressive behavior compared to placebo, but no change in premeditated aggression. It should be noted that subjects with a known history of seizures were excluded from the study, suggesting that effects of anticonvulsants on aggression are independent of effects on seizures. A second study supported the findings of Barratt et al of reduced impulsive aggression in patients treated with phenytoin 83, and a third study showed that effects of phenytoin on impulsive aggression were similar to effects of valproate 84. Phenytoin was well tolerated at the dose used in these studies, which produced blood levels that were on average lower than those used to treat epilepsy.
Valproate/divalproex has also been studied for aggression in several clinical trials. Donovan 85 reported a greater number of children and adolescents with disruptive behavior disorders responding to divalproex compared to placebo for explosive temper and mood lability in a small scale study. Similar results were found in a small scale study comparing valproate to phenytoin and carbamazepine 84. However, another small scale study in patients with pervasive developmental disorders did not find a significant difference between valproate and placebo treated subjects 86. A multicenter placebo controlled trial of divalproex for impulsive aggression also did not find a significant reduction in aggression in patients overall but there was a significantly greater response in the subset of patients with cluster B personality disorders 87. Based on studies to date, a recent Cochrane database meta-analysis concluded that although there is some evidence supporting valproate/divalproex for aggression, further research is warranted 88.
Studies of other anticonvulsants also have reported mixed results in the treatment of aggression. A study by Cueva in patients with conduct disorder did not a difference in response between carbamazepine and placebo 89, but a small-scale study comparing carbamazepine to valproate and phenytoin found that carbamazepine did reduce impulsive aggression although the onset of action of carbamazepine was slower than the other two drugs 84. Similarly, a small scale trial in patients with borderline personality disorder showed decreased behavioral dyscontrol in patients treated with carbamazepine compared to patients treated with placebo 90.
Though research is less extensive, newer anticonvulsants have been reported to reduce aggression in acute laboratory models and in controlled trials. Using a laboratory model of human impulsive aggression, aggressive behavior was diminished following acute doses of Gabapentin 91, Tiagabine 92, and Topirimate 93. In one clinical trial, Topiramate reduced aggression as measured by the Stait Trait Anger Expression Inventory in patients with borderline personality disorder 94. Likewise, oxcarbazepine has been reported to be more efficacious in reducing impulsive aggression in an outpatient trial 95. A few controlled studies have also reported negative results. A trial reported that levetiracetam showed no difference from placebo in reducing impulsive aggression 96.
Selective Serotonin Reuptake Inhibitors
Although selective serotonin reuptake inhibitors (SSRIs) are widely used clinically for the treatment of aggression, there are relatively few controlled trials published on the efficacy of SSRIs for aggression. Fluoxetine is the most widely studied of the SSRIs for aggression. Two studies reported reduced decreased anger 97 and verbal aggression 98 in patients with personality disorders. Another study using fluvoxamine showed a reduction in mood shifts in borderline personality disorder patients treated compared to placebo but no significant difference in aggression scores 99. A more recent study reported that citalopram produced a significant reduction in anger and hostile affect in patients with high hostility scores but who were otherwise healthy 100. The same study reported a reduction in aggression but this only occurred in the female subjects.
There is also some data on effects of SSRIs on aggression in patients with dementia. A study comparing citalopram to risperidone showed that both treatments reduced agitation symptoms and psychotic symptoms but citalopram was associated with fewer side effects 101. Another study of citalopram, perphenazine, and placebo in dementia patients showed that only citalopram was associated with improvement in agitated aggression 102.
Beta Blockers
Although there are relatively few controlled trials with beta adrenergic agonists, where these drugs have been most extensively studied is in patients with a history of traumatic brain injury. A recent Cochrane meta-analysis of the randomized clinical trials for aggression and agitation following brain injury concluded that the best evidence of effectiveness in the management of aggression and agitation in patients with brain injury was for beta blockers 103. However, several caveats were noted in this evidence including the fact that the studies of beta blockers for aggression in brain injury patients were relatively small-scale, used large doses of beta blockers and did not assess global outcomes or long term follow-up. The two beta blockers that have been studied in controlled trials are propranolol 104 and pindolol 105, with neither drug being clearly superior based on the studies to date.
Summary and Conclusions
Aggression is a serious medical problem in a number of neurologic and psychiatric patient groups. It can be a sign of an underlying non-psychiatric medical disorder, or a symptom of a psychiatric or substance use problem. When faced with a patient that has aggressive behavior the most important actions include ensuring safety of the patient and staff, followed closely by an evaluation of the etiology of the aggression. In acute aggression, physical restraints may be needed for a short period until the physical examination and clinical assessment have been made.
Pharmacotherapy for acute aggression involves sedating medications, which have risks in themselves and can make diagnosis difficult. Pharmacotherapy for chronic aggression has as a goal to reduce aggression without producing significant sedation and other side effects. Although there are several controlled trials showing efficacy of several different classes of medications for treatment of chronic aggressive behavior, these studies are relatively small in sample size and none of these medications are approved by the FDA for this indication. Further, all medications have side effects and a recent consensus statement supported the use of pharmacotherapy for aggression and agitation only after non-pharmacologic interventions had failed in patients with dementia due to risk of side effects 106. Thus, non-pharmacologic interventions such as reducing pain, improving sleep, and enhancing unit structure should be applied before pharmacotherapy.
Acknowledgments
Financial support: Supported by R01AA016965 (SDL) and P50DA009262 (FGM)
Footnotes
Financial Disclosures: The authors have nothing to disclose.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Contributor Information
Scott D. Lane, University of Texas Health Science Center at Houston.
Kimberly L. Kjome, University of Texas Health Science Center at Houston.
F. Gerard Moeller, University of Texas Health Science Center at Houston.
References
1. American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV.) 4. Washington DC: APA Press; 1994. [Google Scholar]
2. Archer J. The nature of human aggression. Int J Law Psychiatry. 2009 Jul-Aug;32(4):202–208. [PubMed] [Google Scholar]
3. Moffitt TE. Adolescence-limited and life-course-persistent antisocial behavior: A developmental taxonomy. Psychological Review. 1993;100:674–701. [PubMed] [Google Scholar]
4. Baron RA, Richardson DR. Human aggression. New York: Plenum Press; 1994. [Google Scholar]
5. Cherek DR, Tcheremissine OV, Lane SD. Psychopharmacology of aggression. In: Nelson RJ, editor. Biology of aggression. Oxford, UK: Oxford University Press; 2006. pp. 424–446. [Google Scholar]
6. Cherek DR, Steinberg JL. Psychopharmacology of aggression in humans - laboratory studies. Aggressive Behavior. 1988;14(2):137–137. [Google Scholar]
7. Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev. 2002 May;26(3):321–352. [PubMed] [Google Scholar]
8. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci. 2005 Sep;6(9):691–702. [PubMed] [Google Scholar]
9. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry. 1998 Dec 15;44(12):1239–1247. [PubMed] [Google Scholar]
10. Adolphs R, Tranel D, Damasio H, Damasio A. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature. 1994 Dec 15;372(6507):669–672. [PubMed] [Google Scholar]
11. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001 Jan;6(1):13–34. [PubMed] [Google Scholar]
12. Schoenbaum G, Setlow B, Saddoris MP, Gallagher M. Encoding predicted outcome and acquired value in orbitofrontal cortex during cue sampling depends upon input from basolateral amygdala. Neuron. 2003 Aug 28;39(5):855–867. [PubMed] [Google Scholar]
13. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 1996 Oct 29;351(1346):1413–1420. [PubMed] [Google Scholar]
14. Bechara A, Van Der Linden M. Decision-making and impulse control after frontal lobe injuries. Curr Opin Neurol. 2005 Dec;18(6):734–739. [PubMed] [Google Scholar]
15. Grafman J, Schwab K, Warden D, Pridgen A, Brown HR, Salazar AM. Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology. 1996 May;46(5):1231–1238. [PubMed] [Google Scholar]
16. Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J Psychiatr Res. 1990;24(2):97–109. [PubMed] [Google Scholar]
17. Tonkonogy JM. Violence and temporal lobe lesion: head CT and MRI data. Journal of Neuropsychiatry and Clinical Neurosciences. 1991;3:189–196. [PubMed] [Google Scholar]
18. Brower MC, Price BH. Neuropsychiatry of frontal lobe dysfunction in violent and criminal behaviour: a critical review. Journal of Neurology, Neurosurgery and Psychiatry. 2001 Dec;71(6):720–726. [PMC free article] [PubMed] [Google Scholar]
19. Goodman M, New A, Siever L. Trauma, genes, and the neurobiology of personality disorders. Ann N Y Acad Sci. 2004 Dec;1032:104–116. [PubMed] [Google Scholar]
20. Volkow ND, Tancredi L. Neural substrates of violent behaviour. A preliminary study with positron emission tomography. Br J Psychiatry. 1987 Nov;151:668–673. [PubMed] [Google Scholar]
21. Goyer PF, Andreason PJ, Semple WE, et al. Positron-emission tomography and personality disorders. Neuropsychopharmacology. 1994 Feb;10(1):21–28. [PubMed] [Google Scholar]
22. Yang Y, Glenn AL, Raine A. Brain abnormalities in antisocial individuals: implications for the law. Behav Sci Law. 2008;26(1):65–83. [PubMed] [Google Scholar]
23. New AS, Hazlett EA, Buchsbaum MS, et al. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry. 2002 Jul;59(7):621–629. [PubMed] [Google Scholar]
24. George DT, Rawlings RR, Williams WA, et al. A select group of perpetrators of domestic violence: evidence of decreased metabolism in the right hypothalamus and reduced relationships between cortical/subcortical brain structures in position emission tomography. Psychiatry Res. 2004 Jan 15;130(1):11–25. [PubMed] [Google Scholar]
25. Dougherty DD, Shin LM, Alpert NM, et al. Anger in healthy men: a PET study using script-driven imagery. Biol Psychiatry. 1999 Aug 15;46(4):466–472. [PubMed] [Google Scholar]
26. Raleigh MJ, Steklis HD, Ervin FR, Kling AS, McGuire MT. The effects of orbitofrontal lesions on the aggressive behavior of vervet monkeys (Cercopithecus aethiops sabaeus) Exp Neurol. 1979 Oct;66(1):158–168. [PubMed] [Google Scholar]
27. Marcangelo MJ, Ovsiew F. Psychiatric aspects of epilepsy. Psychiatr Clin North Am. 2007 Dec;30(4):781–802. [PubMed] [Google Scholar]
28. Delgado-Escueta AV, Mattson RH, King L, et al. The nature of aggression during epileptic seizures. Epilepsy Behav. 2002 Dec;3(6):550–556. [PubMed] [Google Scholar]
29. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009 May;5(5):245–255. [PubMed] [Google Scholar]
30. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996 Sep;44(9):1078–1081. [PubMed] [Google Scholar]
31. Association AP. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4. Washington, DC: American Psychiatric Publishing, Inc; 2000. (Text Revision) [Google Scholar]
32. Hodgins S. Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention. Philos Trans R Soc Lond B Biol Sci. 2008 Aug 12;363(1503):2505–2518. [PMC free article] [PubMed] [Google Scholar]
33. Ensor T, Godfrey C. Modelling the interactions between alcohol, crime and the criminal justice system. Addiction. 1993;88:477–487. [PubMed] [Google Scholar]
34. Lanza-Kaduce L, Bishop DM, Winner L. Risk/benefit calculations, moral evaluations, and alcohol use: Exploring the alcohol-crime connection. Crime and Delinquency. 1997;43:222–239. [Google Scholar]
35. Martin SE. The links between alcohol, crime and the criminal justice system: explanations, evidence and interventions. Am J Addict. 2001 Spring;10(2):136–158. [PubMed] [Google Scholar]
36. Murdoch D, Pihl RO, Ross D. Alcohol and crimes of violence: present issues. Int J Addict. 1990 Sep;25(9):1065–1081. [PubMed] [Google Scholar]
37. Galanter M. Recent developments in alcoholism. Alcohol and violence: Epidemiology, neurobiology, psychology, family issues. New York: Plenum Press; 1997. [Google Scholar]
38. Bushman BJ. Effects of alcohol on human aggression. Validity of proposed explanations. Recent Dev Alcohol. 1997;13:227–243. [PubMed] [Google Scholar]
39. Collins JJ, Messerschmidt PM. Epidemiology of alcohol-related violence. Alcohol Health and Research World. 1993;17:93–100. [Google Scholar]
40. Chermack ST, Giancola PR. The relationship between alcohol and aggression: An integrated biopsychosocial conceptualization. Clinical Psychology Review. 1997;17:621–649. [PubMed] [Google Scholar]
41. Giancola PR, White HR, Berman ME, et al. Diverse research on alcohol and aggression in humans: in memory of John A. Carpenter. Alcohol Clin Exp Res. 2003 Feb;27(2):198–208. [PubMed] [Google Scholar]
42. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010 Mar;32(3):403–425. [PubMed] [Google Scholar]
43. Pihl RO, Peterson J. Drugs and aggression - Correlations, crime, and some proposed mechanisms. Journal of Psychiatry & Neuroscience. 1995;20(2):141–149. [PMC free article] [PubMed] [Google Scholar]
44. Berry M. Criminal behavior following drug treatment for psychiatric disorders - Medicolegal and ethical issues. CNS Drugs. 1994;2(4):301–312. [Google Scholar]
45. Bond AJ, Curran HV, Bruce MS, Osullivan G, Shine P. Behavioural aggression in panic disorder after 8 weeks’ treatment with alprazolam. Journal Of Affective Disorders. 1995;35(3):117–123. [PubMed] [Google Scholar]
46. Calhoun SR, Wesson DR, Galloway GP, Smith DE. Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas. Journal Of Psychoactive Drugs. 1996;28(2):183–189. [PubMed] [Google Scholar]
47. Galvan J, Unikel C, Rodriguez EM, Ortiz A, Soriano A, Flores JC. General perspective of flunitrazepam (Rohypnol) abuse in a sample of drug users of Mexico City. Salud Mental. 2000;23(1):1–7. [Google Scholar]
48. Daderman AM, Edman G. Flunitrazepam abuse and personality characteristics in male forensic psychiatric patients. Psychiatry Research. 2001;103(1):27–42. [PubMed] [Google Scholar]
49. Daderman AM, Lidberg L. Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated, grievous violence in male juvenile offenders. Journal Of The American Academy Of Psychiatry And The Law. 1999;27(1):83–99. [PubMed] [Google Scholar]
50. Abel EL. The relationship between cannabis and violence: a review. Psychol Bull. 1977 Mar;84(2):193–211. [PubMed] [Google Scholar]
51. Friedman AS, Glassman K, Terras A. Violent behavior as related to use of marijuana and other drugs. Journal Of Addictive Diseases. 2001;20(1):49–72. [PubMed] [Google Scholar]
52. Brook JS, Brook DW, Rosen Z, Rabbitt CR. Earlier marijuana use and later problem behavior in Colombian youths. J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):485–492. [PubMed] [Google Scholar]
53. Simonds JF, Kashani J. Specific drug use and violence in delinquent boys. Am J Drug Alcohol Abuse. 1980;7(3–4):305–322. [PubMed] [Google Scholar]
54. Poulton R. Cannabis use in young New Zealanders. N Z Med J. 1997 Jul 25;110(1048):279. [PubMed] [Google Scholar]
55. Hoaken PNS, Stewart SH. Drugs of abuse and the elicitation of human aggressive behavior. Addictive Behaviors. 2003;28(9):1533–1554. [PubMed] [Google Scholar]
56. Fals-Stewart W, Golden J, Schumacher JA. Intimate partner violence and substance use: a longitudinal day-to-day examination. Addict Behav. 2003 Dec;28(9):1555–1574. [PubMed] [Google Scholar]
57. Denison ME, Paredes A, Booth JB. Alcohol and cocaine interactions and aggressive behaviors. Recent Dev Alcohol. 1997;13:283–303. [PubMed] [Google Scholar]
58. Davis WM. Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1273–1300. [PubMed] [Google Scholar]
59. Miller NS, Gold MS, Mahler JC. Violent behaviors associated with cocaine use: possible pharmacological mechanisms. Int J Addict. 1991 Oct;26(10):1077–1088. [PubMed] [Google Scholar]
60. Moeller FG, Steinberg JL, Petty F, et al. Serotonin and impulsive/aggressive behavior in cocaine- dependent subjects. Progress In Neuro-Psychopharmacology and Biological Psychiatry. 1994;18(6):1027–1035. [PubMed] [Google Scholar]
61. Moeller FG, Dougherty DM, Rustin T, et al. Antisocial personality disorder and aggression in recently abstinent cocaine dependent subjects. Drug and Alcohol Dependence. 1997 Mar 14;44(2–3):175–182. [PubMed] [Google Scholar]
62. Darke S, Torok M, Kaye S, Ross J, McKetin R. Comparative rates of violent crime among regular methamphetamine and opioid users: offending and victimization. Addiction. 2010;105(5):916–919. [PubMed] [Google Scholar]
63. Bond AJ, Verheyden SL, Wingrove J, Curran HV. Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology. 2004 Jan;171(3):331–339. [PubMed] [Google Scholar]
64. Steadman HJ, Mulvey EP, Monahan J, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry. 1998 May;55(5):393–401. [PubMed] [Google Scholar]
65. Kingery PM, Pruitt BE, Hurley RS. Violence and illegal drug use among adolescents: evidence from the U.S. National Adolescent Student Health Survey. Int J Addict. 1992 Dec;27(12):1445–1464. [PubMed] [Google Scholar]
66. Gillies D, Beck A, McCloud A, Rathbone J. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev. 2005;(4):CD003079. [PubMed] [Google Scholar]
67. Huf G, Coutinho ES, Adams CE. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ. 2007 Oct 27;335(7625):869. [PMC free article] [PubMed] [Google Scholar]
68. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008 Oct;193(4):279–288. [PMC free article] [PubMed] [Google Scholar]
69. Verhoeven WM, Tuinier S. The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study. Journal of Intellectual Disability Research. 1996 Dec;40 (Pt 6):502–508. [PubMed] [Google Scholar]
70. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006 Jun;7(6):492–500. [PubMed] [Google Scholar]
71. Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol. 2001 Aug;11(4):289–293. [PubMed] [Google Scholar]
72. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ. 2005 Apr 16;330(7496):874. [PMC free article] [PubMed] [Google Scholar]
73. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005 Oct;25(5):463–467. [PubMed] [Google Scholar]
74. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69 (Suppl 4):9–14. [PubMed] [Google Scholar]
75. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am. 1997 Jun;20(2):427–451. [PubMed] [Google Scholar]
76. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995;23(4):607–611. [PubMed] [Google Scholar]
77. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976 Dec;133(12):1409–1413. [PubMed] [Google Scholar]
78. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry. 2000 Jul;57(7):649–654. [PubMed] [Google Scholar]
79. Craft M, Ismail IA, Krishnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry. 1987 May;150:685–689. [PubMed] [Google Scholar]
80. Malone RP, Bennett DS, Luebbert JF, et al. Aggression classification and treatment response. Psychopharmacol Bull. 1998;34(1):41–45. [PubMed] [Google Scholar]
81. Glenn MB, Wroblewski B, Parziale J, Levine L, Whyte J, Rosenthal M. Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. Am J Phys Med Rehabil. 1989 Oct;68(5):221–226. [PubMed] [Google Scholar]
82. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. Journal of Clinical Psychopharmacology. 1997 Oct;17(5):341–349. [PubMed] [Google Scholar]
83. Stanford MS, Houston RJ, Mathias CW, Greve KW, Villemarette-Pittman NR, Adams D. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res. 2001 Sep 20;103(2–3):193–203. [PubMed] [Google Scholar]
84. Stanford MS, Helfritz LE, Conklin SM, et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol. 2005 Feb;13(1):72–77. [PubMed] [Google Scholar]
85. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. American Journal of Psychiatry. 2000 May;157(5):818–820. [PubMed] [Google Scholar]
86. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2005 Aug;15(4):682–692. [PubMed] [Google Scholar]
87. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003 Jun;28(6):1186–1197. [PubMed] [Google Scholar]
88. Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev. 2010;(2):CD003499. [PMC free article] [PubMed] [Google Scholar]
89. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1996 Apr;35(4):480–490. [PubMed] [Google Scholar]
90. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry. 1986 Apr;143(4):519–522. [PubMed] [Google Scholar]
91. Cherek DR, Tcheremissine OV, Lane SD, Pietras CJ. Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder. Psychopharmacology (Berl) 2004 Feb;171(4):405–412. [PubMed] [Google Scholar]
92. Lieving LM, Cherek DR, Lane SD, Tcheremissine OV, Nouvion SO. Effects of acute tiagabine administration on aggressive responses of adult male parolees. J Psychopharmacol. 2008 Mar;22(2):144–152. [PubMed] [Google Scholar]
93. Lane SD, Gowin JL, Green CE, Steinberg JL, Moeller FG, Cherek DR. Acute topiramate differentially affects human aggressive responding at low vs. moderate doses in subjects with histories of substance abuse and antisocial behavior. Pharmacol Biochem Behav. 2009 Apr;92(2):357–362. [PMC free article] [PubMed] [Google Scholar]
94. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005 Mar 1;57(5):495–499. [PubMed] [Google Scholar]
95. Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 2005 Dec;25(6):575–579. [PubMed] [Google Scholar]
96. Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 Feb;69(2):310–315. [PubMed] [Google Scholar]
97. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995 Feb;15(1):23–29. [PubMed] [Google Scholar]
98. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997 Dec;54(12):1081–1088. [PubMed] [Google Scholar]
99. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry. 2002 Dec;159(12):2048–2054. [PubMed] [Google Scholar]
100. Kamarck TW, Haskett RF, Muldoon M, et al. Citalopram intervention for hostility: results of a randomized clinical trial. J Consult Clin Psychol. 2009 Feb;77(1):174–188. [PMC free article] [PubMed] [Google Scholar]
101. Pollock BG, Mulsant BH, Rosen J, et al. A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia. Am J Geriatr Psychiatry. 2007 Sep 10; [PubMed] [Google Scholar]
102. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002 Mar;159(3):460–465. [PubMed] [Google Scholar]
103. Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006;(4):CD003299. [PubMed] [Google Scholar]
104. Brooke MM, Patterson DR, Questad KA, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil. 1992 Oct;73(10):917–921. [PubMed] [Google Scholar]
105. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986 Aug;47(8):423–426. [PubMed] [Google Scholar]
106. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008 Jun;69(6):889–898. [PMC free article] [PubMed] [Google Scholar]
